# **Client information/ Contact details**

Please fill out this form and send it back to the following email: [gdugast@domaintherapeutics.com](mailto:gdugast@domaintherapeutics.com)

|  |  |  |
| --- | --- | --- |
| **General information** |  | |
| Number of receptor targets |  | |
| Number of reference compounds per receptor |  | |
| Number of test compounds per receptor |  | |
| Test compounds | Small Molecules  Peptides  Antibodies | |
| Readout | Agonist  Antagonist/allosteric  EC20  EC50  EC80  Dose response curves (22-points)  Single dose  Real time kinetics | |
| Number of independent experiments | N of 1  N of 2 (default) | N of 3  N of 4 |
| Cell host | HEK cells (default)  Other*1*: Provided by Client  Purchased by DTNA  Cell type:  Reference: | |

*1May require an optimization step.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Receptor(s)** |  |  |  |
| Gene Target Name / IUPHAR Nomenclature | Species | Accession Number NM/NP |  |
|  |  |  | Sent by client2  Synthesized by DTNA3 |
|  |  |  | Sent by client2  Synthesized by DTNA3 |
|  |  |  | Sent by client2  Synthesized by DTNA3 |
|  |  |  | Sent by client2  Synthesized by DTNA3 |
|  |  |  | Sent by client2  Synthesized by DTNA3 |

*2 Please send 200 to 500 μg of the mammalian expression vector containing the sequence for functional  
 expression of the receptor of interest.*

*3**DTNA can have the plasmid synthesized for an additional cost of $500 USD.*

|  |  |
| --- | --- |
| **Reference ligand (s) or controls** |  |
|  | Sent by client4  Purchased by DTNA |
|  | Sent by client4  Purchased by DTNA |
|  | Sent by client4  Purchased by DTNA |
|  | Sent by client4  Purchased by DTNA |
|  | Sent by client4  Purchased by DTNA |
|  | Sent by client4  Purchased by DTNA |
|  | Sent by client4  Purchased by DTNA |

*4 Please send compound at a concentration (ideally) of 10 mM (up to 100μL in DMSO). Other formulations can be discussed before shipping. For low potency compounds, higher stock concentrations (up to 100 mM) would be ideal. If shipping powder, please include MW, mass and solubility in DMSO on tubes. To avoid weighing small quantities of powder, the entirety of the tube contents will be solubilized.*

|  |  |  |
| --- | --- | --- |
| **Sensors** |  |  |
| G protein activation5 | **GAPL-Gas**  GAPL-Gai1  **GAPL-Gai2**  GAPL-Gai3  GAPL-GaoA  **GAPL-GaoB**  **GAPL-Gaz** | GAPL-Ga12  **GAPL-Ga13**  **GAPL-Gaq**  GAPL-Ga11  GAPL-Ga14  **GAPL-Ga15** |
| b-Arrestin recruitment | b-Arrestin 1-PM | b-Arrestin 1-PM + GRK2  b-Arrestin 1-PM + GRK5  b-Arrestin 1-PM + GRK6 |
| b-Arrestin 2-PM | **b-Arrestin 2-PM + GRK2**  b-Arrestin 1-PM + GRK5  b-Arrestin 1-PM + GRK6 |
| Internalization/trafficking | Receptor-PM  Receptor-Endo  b-Arrestin 2-Endo | |
| cAMP | EPAC sensor (Gs mode)  EPAC sensor (Gi mode) | |

*5 The core 8 biosensor panel provides coverage of all 4 G protein families (sensors in bold) and offer a  
 first insight into potential signaling bias exhibited by the ligands of interest.*

|  |  |
| --- | --- |
| **Additional information** |  |
|  | |